Oncolytic virus

Results: 117



#Item
81John C. Bell, PhD Senior Scientist, Cancer Therapeutics, Ottawa Hospital Research Institute Professor, Depts. of Medicine and Biochemistry, Microbiology & Immunology University of Ottawa Research Interests Oncolytic Viru

John C. Bell, PhD Senior Scientist, Cancer Therapeutics, Ottawa Hospital Research Institute Professor, Depts. of Medicine and Biochemistry, Microbiology & Immunology University of Ottawa Research Interests Oncolytic Viru

Add to Reading List

Source URL: www.montrealiums2014.org

Language: English - Date: 2014-05-26 14:19:19
82Acta Med. Okayama, 2011 Vol. 65, No. 3, pp. 151ﾝ162 CopyrightⒸ 2011 by Okayama University Medical School. http://escholarship.lib.okayama-u.ac.jp/amo/

Acta Med. Okayama, 2011 Vol. 65, No. 3, pp. 151ﾝ162 CopyrightⒸ 2011 by Okayama University Medical School. http://escholarship.lib.okayama-u.ac.jp/amo/

Add to Reading List

Source URL: www.lib.okayama-u.ac.jp

Language: English - Date: 2011-06-27 22:01:26
83Results of world-first viral therapy trial in Ottawa cancer patients published in Nature Researchers from the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa), Jennerex Inc. and several other

Results of world-first viral therapy trial in Ottawa cancer patients published in Nature Researchers from the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa), Jennerex Inc. and several other

Add to Reading List

Source URL: ohfoundation.ca

Language: English - Date: 2012-07-26 14:23:08
84PSIOXUS THERAPEUTICS STRENGTHENS TEAM WITH TWO APPOINTMENTS Addition of Non-Executive Board Director and Expanded Scientific Advisory Board Position Development Stage Biotech for Growth and Commercialisation LONDON – 1

PSIOXUS THERAPEUTICS STRENGTHENS TEAM WITH TWO APPOINTMENTS Addition of Non-Executive Board Director and Expanded Scientific Advisory Board Position Development Stage Biotech for Growth and Commercialisation LONDON – 1

Add to Reading List

Source URL: www.psioxus.com

Language: English - Date: 2012-01-18 05:15:55
85Sarcopenia / Cachexia / Oncolytic virus / Medicine / Geriatrics / Rehabilitation medicine

FOR IMMEDIATE RELEASE MYOTEC THERAPEUTICS COMPLETES MERGER WITH HYBRID BIOSYSTEMS TO FORM PSIOXUS THERAPEUTICS

Add to Reading List

Source URL: www.psioxus.com

Language: English - Date: 2011-03-31 12:28:13
86PSIOXUS THERAPEUTICS RECEIVES £1.8 MILLION TRANSLATION AWARD FROM THE WELLCOME TRUST TO TAKE ONCOLYTIC VIRUS INTO CLINIC ColoAd1 will enter phase I/II development for metastatic colorectal cancer in 2012 LONDON –12 Se

PSIOXUS THERAPEUTICS RECEIVES £1.8 MILLION TRANSLATION AWARD FROM THE WELLCOME TRUST TO TAKE ONCOLYTIC VIRUS INTO CLINIC ColoAd1 will enter phase I/II development for metastatic colorectal cancer in 2012 LONDON –12 Se

Add to Reading List

Source URL: www.psioxus.com

Language: English - Date: 2011-12-20 03:27:39
87Early Success of Ark’s Manufacturing Partnership with PsiOxus Initiation of Toxicology Study for PsiOxus’s ColoAd1 Oncolytic Product London, UK - 4 January 2012, Ark Therapeutics Group plc (“Ark”) and PsiOxus The

Early Success of Ark’s Manufacturing Partnership with PsiOxus Initiation of Toxicology Study for PsiOxus’s ColoAd1 Oncolytic Product London, UK - 4 January 2012, Ark Therapeutics Group plc (“Ark”) and PsiOxus The

Add to Reading List

Source URL: www.psioxus.com

Language: English - Date: 2012-01-04 06:08:27
88FOR IMMEDIATE RELEASE PSIOXUS THERAPEUTICS SECURES £22 MILLION ($34 MILLION) IN SERIES B FINANCING TO DRIVE CLINICAL DEVELOPMENT FOR ONCOLYTIC VACCINE Investment to Advance ColoAd1 through Phase II Clinical Trial for

FOR IMMEDIATE RELEASE PSIOXUS THERAPEUTICS SECURES £22 MILLION ($34 MILLION) IN SERIES B FINANCING TO DRIVE CLINICAL DEVELOPMENT FOR ONCOLYTIC VACCINE Investment to Advance ColoAd1 through Phase II Clinical Trial for

Add to Reading List

Source URL: www.psioxus.com

Language: English - Date: 2012-07-09 04:32:34
89INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE 25 October 2006 ICH Considerations General Principles to Address the Risk of Inadvertent Germline Inte

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE 25 October 2006 ICH Considerations General Principles to Address the Risk of Inadvertent Germline Inte

Add to Reading List

Source URL: www.ich.org

Language: English - Date: 2012-06-22 05:07:33
90INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009

Add to Reading List

Source URL: www.ich.org

Language: English - Date: 2012-06-22 05:07:32